Literature DB >> 16356309

Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.

Alan P Venook1, Charles D Blanke, Donna Niedzwiecki, Heinz-Josef Lenz, John R Taylor, Donna R Hollis, Susan Sutherland, Richard M Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16356309     DOI： 10.3816/ccc.2005.n.043

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  11 in total

Review 1.  Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.

Authors:  Kristen K Ciombor; Richard M Goldberg
Journal:  Hepat Oncol       Date:  2014-09-09

Review 2.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Authors:  Jean-Baptiste Bachet; Lucie Peuvrel; Claude Bachmeyer; Ziad Reguiai; Pierre A Gourraud; Olivier Bouché; Marc Ychou; Rene J Bensadoun; Brigitte Dreno; Thierry André
Journal:  Oncologist       Date:  2012-03-16

3.  Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment.

Authors:  Long Bai; Dong-Sheng Zhang; Wen-Jing Wu; Chao Ren; De-Shen Wang; Feng Wang; Miao-Zhen Qiu; Rui-Hua Xu
Journal:  Med Oncol       Date:  2015-01-13       Impact factor: 3.064

4.  The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials.

Authors:  Yingqian Lv; Zixin Yang; Li Zhao; Shan Zhao; Jinzhu Han; Likang Zheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 5.  New target-based agents involve new clinical trial designs.

Authors:  Coralia Bueno Muíño; José Angel García-Sáenz; Sara López Tarruella; Laura Rodríguez Lajustica; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

6.  Which strategies will lead to progress in the management of colorectal cancer?

Authors:  Richard M Goldberg
Journal:  Gastrointest Cancer Res       Date:  2007

7.  Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence - A retrospective single-center study.

Authors:  Yanhong Deng; Yue Cai; Jiayu Lin; Ling Jiang; Huabin Hu
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-13

Review 8.  Targeting metastatic colorectal cancer - present and emerging treatment options.

Authors:  Kristen K Ciombor; Jordan Berlin
Journal:  Pharmgenomics Pers Med       Date:  2014-07-08

9.  High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

Authors:  Christina Siesing; Halfdan Sorbye; Anca Dragomir; Per Pfeiffer; Camilla Qvortrup; Fredrik Pontén; Karin Jirström; Bengt Glimelius; Jakob Eberhard
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

10.  Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Authors:  John L Marshall
Journal:  J Oncol       Date:  2009-12-06       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.